Had a golden opportunity to share a case on how we manage patient with CKD from cardiologist point of view along with Dato Sri Dr Azhari Rosman!
It was a well organized talk attended by a group of 20 Gps!
Empagliflozin is an SGLT-2 inhibitor originally used for managing type 2 diabetes. Recent studies have shown its efficacy in treating chronic kidney disease (CKD), regardless of diabetic status. By reducing blood glucose levels, empagliflozin also helps to lower blood pressure, reduce proteinuria, and mitigate the progression of kidney damage.
Great Q&A sessions about SGLT2i and as well as general cardiology questions.
The EMPA-KIDNEY trial demonstrated significant benefits, showing that empagliflozin slows down CKD progression, reduces cardiovascular risk, and lowers the likelihood of hospitalization due to heart failure. Its kidney-protective effects are believed to stem from reducing intraglomerular pressure, improving metabolic parameters, and decreasing inflammation and fibrosis in the kidneys.
I have learnt alot from Dato Sri as well as the GPs!
Overall, empagliflozin represents a promising treatment option for CKD patients, with or without diabetes, offering improved renal and cardiovascular outcomes.
Grateful for the opportunity given and hope to have more in future!